Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial.
Emma Guttman-YasskyJonathan Ian SilverbergDiamant ThaçiKim A PappSonja StänderLisa A BeckBrian S KimXiaofei HuJianzhong LiuBrian M CalimlimNamita VignaJameson T CrowleyHenrique D TeixeiraJacob Pontoppidan ThyssenPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Continuous treatment with upadacitinib is suggested to maintain skin clearance and antipruritic effects.